Physician profile
Samuel D Hoeper
NPI 1700877792
$2,238.57
in general payments reported to CMS, 2019-2025
26 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $585 · 2020: $346 · 2021: $956 · 2022: $351.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $324.63 | 2019-2022 | |
| Pfizer INC. | $303.06 | 2019-2022 | |
| Amgen INC. | $231.07 | 2019-2022 | |
| Novo Nordisk INC | $186.77 | 2019-2022 | |
| Abbvie INC. | $152.25 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $124.38 | 2020-2022 | |
| Merck Sharp & Dohme LLC | $102.25 | 2021-2022 | |
| Eisai INC. | $91.00 | 2020-2021 | |
| Sanofi-Aventis U.S. LLC | $88.31 | 2019-2021 | |
| Astrazeneca Pharmaceuticals LP | $81.53 | 2019-2022 | |
| Glaxosmithkline, LLC. | $78.86 | 2020-2022 | |
| Novartis Pharmaceuticals Corporation | $59.25 | 2019-2022 | |
| E.R. Squibb & Sons, L.L.C. | $55.37 | 2019-2022 | |
| Astellas Pharma US INC | $49.95 | 2019 | |
| Janssen Pharmaceuticals, INC | $39.48 | 2019-2021 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kowa Pharmaceuticals America, INC. | $39.44 | 2020-2021 | |
| Teva Pharmaceuticals USA, INC. | $37.35 | 2020 | |
| Sanofi Pasteur INC. | $36.23 | 2019-2020 | |
| Sunovion Pharmaceuticals INC. | $28.88 | 2021 | |
| Biogen, INC. | $25.83 | 2021 | |
| Tersera Therapeutics LLC | $24.72 | 2019 | |
| Medtronic Vascular, INC. | $18.97 | 2019 | |
| Esperion Therapeutics, INC. | $16.01 | 2021 | |
| Abbott Laboratories | $15.80 | 2022 | |
| Boston Scientific Corporation | $15.51 | 2021 | |
| Becton, Dickinson and Company | $11.67 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Samuel Hoeper listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.